血清DCN、NRG-1、MIF水平与首发未服药精神分裂症患者临床症状和认知功能的相关性分析

目的:探讨血清核心蛋白多糖(DCN)、神经调节蛋白-1(NRG-1)、巨噬细胞迁移抑制因子(MIF)水平与首发未服药精神分裂症患者临床症状和认知功能的相关性。方法:选择2018年1月~2020年11月期间长江大学附属第一医院收治的首发未服药精神分裂症患者80例作为精神分裂症组,同期于长江大学附属第一医院进行体检的健康志愿者80例作为对照组。应用阳性和阴性症状量表(PANSS)评估患者精神病理症状,应用MATRICS共识认知成套测验(MCCB)评估所有受试者认知功能。根据PANSS评分将精神分裂症组分为PANSS评分高分组和低分组,比较两组血清DCN、NRG-1、MIF水平,并分析以上指标水平与PANSS总分、MCCB各项评分的相关性。结果:精神分裂症组患者PANSS总分为(77.18±13.57)分。精神分裂症组MCCB各项评分均低于对照组(P<0.05)。精神分裂症组血清DCN、NRG-1水平低于对照组,MIF水平高于对照组(P<0.05)。PANSS高分组血清DCN、NRG-1水平低于PANSS低分组,MIF水平高于PANSS低分组(P<0.05)。Pearson相关性分析显示,首发未服药精神分裂症患者血清DCN、NRG-1水平与PANSS总分呈负相关,与MCCB各项评分呈正相关,MIF水平与PANSS总分呈正相关,与MCCB各项评分呈负相关(均P<0.05)。结论:首发未服药精神分裂症患者血清DCN、NRG-1、MIF水平异常,且以上指标水平与患者临床症状和认知功能受损有一定联系,提示检测以上指标水平可能为该病患者认知功能及临床症状的评估提供参考。     

DTI和功能磁共振成像对精神分裂症患者脑功能连接强度的临床研究

摘要 目的：探讨DTI和功能磁共振成像对精神分裂症患者脑功能连接强度的临床研究。方法：选取2017年9月-2021年3月在我院精神科就诊的精神分裂患者96例。将纳入的96例患者作为精神分裂组,选择同时期招募的96例健康志愿者作为对照组。使用FMRIB软件库进行结构数据预处理和脑解剖网络构建,并进行相关的分析。结果：精神分裂组较对照组枕叶模块功能连接强度增强,较对照组皮质模块和额顶叶模块功能连接强度减弱（P<0.05）,精神分裂组与对照组的默认模块和中央模块功能连接强度比较无差异（P>0.05）。精神分裂组与对照组各模块的结构连接强度比较无差异（P>0.05）。精神分裂组较对照组默认模式模块和中央模块的结构-功能连接程度增加,精神分裂组较对照组枕叶模块和皮质模块的结构-功能连接程度降低（P<0.05）,额顶叶模块结构-功能连接程度两组比较无差异（P>0.05）。在精神分裂症组中,枕叶模块的结构-功能连接评分与疾病持续时间（r=-0.528,P=0.006）和PANSS总体症状相关（r=-0.174,P=0.003）,皮质模块的结构-功能连接评分也与PANSS整体症状（r=-0.405,P=0.034）显著负相关。皮质模块的结构-功能连接评分与疾病持续时间之间显著负相关（r=-0.336,P=0.029）。结论：精神分裂症患者的脑功能连接强度（功能模块水平上结构-功能耦合）发生改变,其结构-功能耦合的畸变与精神分裂症的临床特征相关。     

Modulating effect of Val66Met polymorphism of brain-derived neurotrophic factor gene on clinical and psychological characteristics of patients with schizophrenia

The brain-derived neurotrophic factor (BDNF) gene is an important candidate gene for schizophrenia. The association of BDNF with schizophrenia has been extensively analyzed using the polymorphism Val66Met. There is accumulating evidence that Val66Met is associated with clinical presentations of schizophrenia rather than with the disease itself. In this study, BDNF allele and genotype distributions were compared in patients (n = 1785) and healthy controls (n = 1092). There was no association between the Val66Met polymorphism and schizophrenia. The marker was not associated with the presence of the affective syndrome either. At the same time, the ValVal genotype was associated with higher anxiety levels in male patients as assessed with PANSS. Patients’ personality traits were characterized using the personality inventories EPI, MMPI, and STAI (n = 363), and their cognitive functions, attention (n = 282) and verbal fluency (n = 392), were evaluated. Patients with the ValVal genotype showed higher levels of anxiety (by MMPI) and better performance on neurocognitive tests. The genotype and trait anxiety (by STAI score) had an interaction effect on cognitive functions. In patients with higher anxiety, performance on cognitive tests did not depend on the genotype, while in patients with lower levels of anxiety, the ValVal genotype was associated with significantly better performance. This effect should be taken into account when studying associations of the Val66Met polymorphism with cognitive functions in patients with schizophrenia.     

The Interaction of Polymorphisms of IL10 and DBH Was Associated with General Symptoms of PANSS with TD in Chinese Han Schizophrenic Patients

Objective

Tardive dyskinesia (TD) is a human hyperkinetic movement disorder as a result of potentially irreversible long-term chronic first-generation antipsychotic medications. Unfortunately, mechanisms involved in the development of TD have been poorly understood. Previous studies have indicated that some genetic polymorphisms of immune system and dopamine beta-hydroxylase (DBH) genes may be involved in the pathogenesis of TD. Rs1800872 and rs72393728 are located on the promoter of interleukin-10 (IL10) and DBH gene, respectively. The genetic association between the rs1800872 and TD is unclear. Previous studies have indicated that genetic variations of IL 10 and DBH are implicated in the positive and negative symptoms in schizophrenia. However, the interaction of two variations with severity of TD and symptoms of schizophrenic patients with TD has not been reported. The present study investigated whether these variations and their interaction were associated with clinical phenotypes of TD with schizophrenia in a genetically homogeneous northern Chinese Han population.

Methods

Rs1800872 and rs72393728 were genotyped in schizophrenic patients with TD (n = 372) and without TD (NTD; n = 412). The Abnormal Involuntary Movement Scale (AIMS) and Positive and Negative Syndrome Scale (PANSS) were applied to assess the severity of TD and psychopathology of schizophrenia, respectively.

Results

The allele and genotype frequencies of rs1800872 and rs72393728 did not significantly differ between TD and NTD patients (p>0.05). No significant difference was found in the AIMS total score among the genotypes of two loci (p>0.05). Interestingly, the interaction of rs1800872 and rs72393728 showed a significant association with the PANSS general score (p = 0.011), and a trend toward to the PANSS total score (p = 0.055).

Conclusion

These findings suggest that the interaction of rs1800872 and rs72393728 variants may play a role in psychopathology of the general symptoms on PANSS in schizophrenic patients with TD in a northern Chinese Han population.     

阿立哌唑与利培酮治疗难治性精神分裂症的临床疗效对比

目的:研究对比阿立哌唑与利培酮治疗难治性精神分裂症(简称难治性精分症)的临床疗效。方法:选择2012年6月至2015年5月在我院接受治疗的难治性精分症患者108例进行研究。根据数字法随机将患者分成观察组及对照组各54例,观察组给予阿立哌唑治疗,对照组给予利培酮治疗,8周后对比两组治疗后的总体疗效,不良反应情况,以及不同时期阴性与阳性症状量表(PANSS)评分值。结果:观察组治疗后的总有效率92.59%,显著高于照组的77.78%(P0.05)。两组治疗1周后~治疗8周后的阳性症状、阴性症状、一般病理及PANSS总分均分别显著低于治疗前的水平(P0.05),且观察组治疗1周后~治疗8周后的阴性症状及PANSS总分均分别显著低于对照组(P0.05)。观察组治疗后的不良反应总发生率为33.33%,显著低于对照组的64.81%(P0.05)。结论:阿立哌唑较利培酮治疗难治性精分症可获得更好的疗效及安全性,建议可在临床进一步研究和推广应用。     

Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia

Background

Patients with schizophrenia perform significantly worse on emotion recognition tasks than healthy participants across several sensory modalities. Emotion recognition abilities are correlated with the severity of clinical symptoms, particularly negative symptoms. However, the relationships between specific deficits of emotion recognition across sensory modalities and the presentation of psychotic symptoms remain unclear. The current study aims to explore how emotion recognition ability across modalities and neurocognitive function correlate with clusters of psychotic symptoms in patients with schizophrenia.

Methods

111 participants who met the DSM-IV diagnostic criteria for schizophrenia and 70 healthy participants performed on a dual-modality emotion recognition task, the Diagnostic Analysis of Nonverbal Accuracy 2-Taiwan version (DANVA-2-TW), and selected subscales of WAIS-III. Of all, 92 patients received neurocognitive evaluations, including CPT and WCST. These patients also received the PANSS for clinical evaluation of symptomatology.

Results

The emotion recognition ability of patients with schizophrenia was significantly worse than healthy participants in both facial and vocal modalities, particularly fearful emotion. An inverse correlation was noted between PANSS total score and recognition accuracy for happy emotion. The difficulty of happy emotion recognition and earlier age of onset, together with the perseveration error in WCST predicted total PANSS score. Furthermore, accuracy of happy emotion and the age of onset were the only two significant predictors of delusion/hallucination. All the associations with happy emotion recognition primarily concerned happy prosody.

Discussion

Deficits in emotional processing in specific categories, i.e. in happy emotion, together with deficit in executive function, may reflect dysfunction of brain systems underlying severity of psychotic symptoms, in particular the positive dimension.     

Therapeutic effects of maximal strength training on walking efficiency in patients with schizophrenia - a pilot study

ABSTRACT: BACKGROUND: Patients with schizophrenia frequently have disabling gait deficits. The net mechanical efficiency of walking (epsilonnet) is an accurate measure often used to evaluate walking performance. Patients with gait deficits have a reduced epsilonnet with excessive energy expenditure during sub-maximal walking. Maximal strength training (MST) improves epsilonnet in healthy individuals and is associated with reduced risk of mortality. The aim of this study was to investigate whether MST improves epsilonnet in patients with schizophrenia. METHODS: Patients (ICD-10 schizophrenia, schizotypal or delusional disorders (F20-F29)) were included in a non-randomized trial. Patients were assigned to one of two groups: 1) MST consisting of 4x4 repetitions at 85-90% one repetition maximum (1RM) performed in a leg press apparatus or 2) playing computer games (CG). Both groups carried out their activity three days per week for eight weeks. 1RM, epsilonnet at 60 watt walking, peak oxygen uptake (VO2peak), the Positive and Negative Syndrome Scale (PANSS) and the 36-items short form (SF-36) were measured pre and post intervention. RESULTS: The baseline epsilonnet was 17.3 +/- 1.2% and 19.4 +/- 3.0% in the MST (n = 6) and CG groups (n = 7), respectively, which is categorized as mechanical inefficiency. The MST group improved 1RM by 79 kg (p = 0.006) and epsilonnet by 3.4% (p = 0.046) more than the CG group. The MST group improved 1RM and epsilonnet, by a mean of 83 kg (p = 0.028) and 3.4% (p = 0.028), respectively. VO2peak at baseline was 34.2 +/- 10.2 and 38.3 +/- 9.8 ml * kg-1 * min-1 in the MST and CG groups, respectively, and did not change (p > 0.05). No change was observed in PANSS or SF-36 (p > 0.05). CONCLUSIONS: MST improves 1RM and epsilonnet in patients with schizophrenia. MST could be used as a therapeutic intervention for patients with schizophrenia to normalize their reduced epsilonnet.     

重复经颅磁刺激对慢性精神分裂症患者认知功能影响的初步研究

目的:探讨重复经颅磁刺激(rTMS)对慢性精神分裂症患者认知功能的影响。方法:100例慢性精神分裂症患者,按照随机数字表法分为rTMS真刺激组和伪刺激组,每组各50例。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评估患者治疗前后精神症状及不良反应;采用威斯康星卡片分类测验(WCST)及可重复的成套神经心理状态测量(RBANS)评价患者治疗前后认知功能。结果:治疗后,rTMS真刺激组PANSS总分、阳性量表分、阴性量表分、一般精神病理量表分均明显降低(P0.05),且均明显低于伪刺激组(P0.05),两组治疗前后及组间TESS评分无明显差异(P0.05);rTMS真刺激组WCST中的概念化水平百分数明显高于伪刺激组(P0.05),总时间及错误思考时间短于伪刺激组(P0.05);rTMS真刺激组RBANS中视觉广度与延迟记忆成绩明显提高(P0.05),且视觉广度明显高于伪刺激组(P0.05);rTMS真刺激组2例患者首次治疗后出现轻度不适症状,随访3个月所有患者均无不适主诉。结论:rTMS治疗对慢性精神分裂症患者的部分认知功能有一定的改善作用,且安全性较高,值得进一步研究。     

Enzymatic activity of palmitoyl‐protein thioesterase‐1 in serum from schizophrenia significantly associates with schizophrenia diagnosis scales

Genome‐wide association studies have confirmed that schizophrenia is an inheritable multiple‐gene mental disorder. Longitudinal studies about depression, first episode psychosis (FEP) and acute psychotic relapse have mostly searched for brain imaging biomarkers and inflammatory markers from the blood. However, to the best of our knowledge, the association between enzymatic activities with diagnosis or prediction of treatment response in people with schizophrenia has barely been validated. Under the Longitudinal Study of National Mental Health Work Plan (2015‐2020), we have studied a subsample of approximately 36 individuals from the cohort with data on palmitoyl‐protein thioesterase‐1 enzymatic activity from FEP and performed a bivariate correlation analysis with psychiatric assessment scores. After adjusting for sex, age, body mass index (BMI) and total serum protein, our data demonstrated that PPT1 enzymatic activity is significantly associated with schizophrenia and its Positive and Negative Syndrome Scale (PANSS) scores. This longitudinal study compared the PPT1 enzymatic activity in FEP schizophrenia patients and healthy volunteers, and the former exhibited a significant 1.5‐fold increase in PPT1 enzymatic levels (1.79 mmol/L/h/mL, and 1.18 mmol/L/h/mL; P < 0.05; 95% CI, 2.3‐2.9 and 1.4‐1.8). The higher PPT1 enzymatic levels in FEP schizophrenia patients were positively associated with larger PANSS scaling scores (r = 0.32, P = 0.0079 for positive scaling; r = 0.41, P = 0.0006 for negative scaling; r = 0.45, P = 0.0001 for general scaling; and r = 0.34, P = 0.0048 for PNASS‐S scaling). Higher enzymatic PPT1 in FEP schizophrenia patients is significantly associated with increased PANSS scaling values, indicating more serious rates of developing psychosis. Enzymatic activity of PPT1 may provide an important new view for schizophrenia disorders.     

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia

Background

This therapeutic drug monitoring (TDM) study aimed to determine the role of olanzapine (OLZ) and N-desmethyl-OLZ (DMO) levels in the therapeutic efficacy of OLZ in patients with schizophrenia.

Method

Plasma concentrations of OLZ (C_OLZ) and DMO (C_DMO) in schizophrenic patients 12 hours post-dose were assessed. The correlations of C_OLZ and C_DMO with the various scores of the Positive and Negative Syndrome Scale (PANSS) were evaluated. A receiver operating characteristic curve (ROC) was utilized to identify the threshold C_OLZ and C_OLZ/C_DMO ratio for maintenance of satisfactory efficacy.

Results

A total of 151 samples from patients with schizophrenia were analyzed for individual C_OLZ and C_DMO levels. The mean C_OLZ and C_DMO levels were 37.0 ± 25.6 and 6.9 ± 4.7 ng/mL, respectively, and C_OLZ was ~50% higher in female or nonsmokers (p<0.01). In all patients, the daily dose of OLZ was positively correlated with C_OLZ and C_DMO. Linear relationships between C_OLZ and OLZ dose were observed in both nonsmokers and smokers (r_s = 0.306, 0.426, p<0.01), although C_DMO was only correlated with OLZ dose in smokers (r_s = 0.485, p<0.01) and not nonsmokers. In all patients, C_OLZ was marginally negatively correlated with the total PANSS score. The total PANSS score was significantly negatively correlated with the C_OLZ/C_DMO ratio (p<0.005), except in smokers. The ROC analysis identified a C_OLZ/C_DMO ratio ≥2.99 or C_OLZ ≥22.77 ng/mL as a predictor of maintenance of an at least mildly ill status (PANSS score ≤58) of schizophrenia in all patients.

Conclusions

A significantly negative correlation between the steady-state C_OLZ/C_DMO ratio and total PANSS score was observed in Taiwanese schizophrenic patients. TDM of both OLZ and DMO levels could assist clinical practice when individualizing OLZ dosage adjustments for patients with schizophrenia.     

The Effects of an Animal-Assisted Intervention on Salivary Alpha-Amylase,Salivary Immunoglobulin A,and Heart Rate during Forensic Interviews in Child Sexual Abuse Cases

Animal-assisted invention (AAI) in gaining attention as a therapeutic modality; however, the effect of it has not been well studied in the child welfare system. The purpose of this study was to examine the effects of AAI on stress indicators (as measured by salivary alpha-amylase (sAA), immunoglobulin A (IgA), and heart rate) in children undergoing forensic interviews for alleged sexual abuse. A repeated measures design was used in this study. Upon receiving signed, informed consents and assents, children were enrolled in the study. Children (n = 42), whose ages ranged from 5 to 14 years (M = 8.91, SD = 2.33), were assigned to either the intervention condition (n = 19; AAI during forensic interview) or the control condition (n = 23; standard practice forensic interview). Each child's parent/guardian completed a demographic form, and saliva samples and heart rate measures were obtained from each child before and after the forensic interview. Mixed linear models were tested, with the level of significance set at p ≤ 0.05. There was an interactive effect regarding the duration of the interview and the presence of the dog on sAA after the forensic interview (p = 0.047). There also was a significant interaction between age and length of interview (p = 0.01). Salivary immunoglobulin A tended to be lower (p = 0.055) when the therapy dog was present during the forensic interview. Results further indicated that the drop in heart rate was greater in longer interviews and with older children (p = 0.02) when the dog was present. Individuals working in child welfare systems can use the results of this study to advocate for the use of therapy dogs as a therapeutic intervention. More research is needed to further examine the relationships among AAI, salivary biomarkers, and stress responses in children to improve child welfare.     

Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors

The aim of this study was to determine the plasma selenium (Se), copper (Cu), and zinc (Zn) levels and to evaluate their possible association with metabolic syndrome (MetS) components in patients with schizophrenia. The study group consisted of 60 patients with schizophrenia and 60 sex- and age-matched healthy controls. Anthropometric measurements, blood pressure, and biochemical analysis of fasting blood were performed in all subjects. Patients with schizophrenia had significantly higher plasma Cu concentrations compared with controls (0.97?±?0.31 vs. 0.77?±?0.32 mg/L, p?=?0.001). The plasma Cu concentration showed a positive correlation with plasma glucose and diastolic blood pressure in the patient groups (r _s ?=?0.263, p?<?0.05 and r _s ?=?0.272, p?<?0.05, respectively). The plasma Se level correlated positive with MetS score (r _s ?=?0.385, p?<?0.01), waist circumference (r _s ?=?0.344, p?<?0.05), plasma glucose (r _s ?=?0.319, p?<?0.05), and triglyceride concentrations (r _s ?=?0.462, p?<?0.001) in patients with schizophrenia. Plasma Zn did not correlate with any of the MetS components. These results suggest that alterations in plasma Cu and Se levels in medicated patients with schizophrenia could be associated with metabolic risk factors.     

Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese

Although dysfunction of catechol‐O‐methyltransferase (COMT)‐mediated dopamine transmission is implicated in the etiology of schizophrenia, the human COMT gene has not been associated consistently with schizophrenia. The purpose of this study was to investigate whether the COMT gene is associated with the development of schizophrenia and whether the polymorphisms of this gene influence the psychopathological symptoms in patients with schizophrenia. Fourteen polymorphisms of the COMT gene were analyzed in a case–control study of 876 Han Chinese individuals (434 patients and 442 controls). All participants were screened using a Chinese version of the modified Schedule for Affective Disorders and Schizophrenia‐Lifetime Version (SADS‐L) and all patients met the criteria for schizophrenia. Furthermore, pretreatment of psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) in a subset of 224 hospitalized schizophrenia patients, who were drug‐naÏve or drug‐free, to examine the association between clinical symptomatology and COMT polymorphisms. No significant differences in allele or genotype frequencies were observed between schizophrenia patients and controls, for all variants investigated. Haplotype analysis showed that three haplotype blocks of the COMT gene were not associated with the development of schizophrenia. Moreover, these COMT polymorphisms did not influence the PANSS scores of schizophrenia patients. This study suggests that the COMT gene may not contribute to the risk of schizophrenia and to the psychopathological symptoms of schizophrenia among Han Chinese.     

右美托咪定和丙泊酚用于电休克治疗联合奥氮平治疗精神分裂症疗效的影响

摘要 目的：探究精神分裂症患者联用奥氮平与电休克治疗的可行性,并分析电休克治疗前应用右美托咪定和丙泊酚对患者应激反应的影响。方法：选择2019年4月至2021年4月在我院接受治疗的120例精神分裂症患者为研究对象,将其按照随机数字表法区分为A组、B组和C组（每组各40例患者）,A组患者单纯接受奥氮平治疗,B组患者在A组基础上加用电休克治疗（术前使用丙泊酚麻醉）,C组在B组电休克治疗基础上加用右美托咪定麻醉,就A组和B组患者治疗前后的PANSS评分及治疗效果进行比较,就B组和C组患者血流动力学指标、电休克治疗指标以及不良反应发生率进行比较。结果：（1）治疗前两组患者PANSS量表中阳性症状、阴性症状、一般精神病理及总分组间无差异（P>0.05）,治疗6周后B组患者阳性症状、阴性症状、一般精神病理及总分均明显低于A组（P<0.05）;（2）麻醉前（T0）时两组患者的HR、MAP组间比较无差异（P>0.05）,而在麻醉给药10 min（T1）和电击后5 min（T2）时,C组患者的HR与MAP均低于B组（P<0.05）;（3）B组与C组患者电休克治疗的相关指标诸如苏醒时间、自主呼吸恢复时间以及能量抑制指数上组间无差异（P>0.05）;（4）B组患者呃逆、躁动、头痛等不良反应总发生率为32.50 %（13/40）高于C组患者上述不良反应总发生率5.00 %（2/40）（P<0.05）。结论：电休克治疗联合奥氮平对精神分裂症具有较好的治疗效果,术前若能够联用右美托咪定和丙泊酚进行麻醉,将显著改善患者应激症状,降低术后各类并发症发生率。     

Body mass effects of a physical activity and healthy food intervention in middle schools

Objective: To evaluate the effects of a 2‐year middle school physical activity and healthy food intervention, including an environmental and computer‐tailored component on BMI and BMI z‐score in boys and girls. Research Methods and Procedures: A random sample of 15 schools with seventh and eighth graders was randomly assigned to three conditions: an intervention with parental support group, an intervention‐alone group, and a control group. Weight and height were measured at the beginning and end of each school year to assess BMI and BMI z‐score. A physical activity and healthy food program was implemented over 2 school years. Results: In girls, BMI and BMI z‐score increased significantly less in the intervention with parental support group compared with the control group (p < 0.05) or the intervention‐alone group (p = 0.05). In boys, no significant positive intervention effects were found. Discussion: This was the first study evaluating the effectiveness of an intervention combining environmental changes with personal computer‐tailored feedback on BMI and BMI z‐score in middle school children. After 2 school years, BMI and BMI z‐score changed in a more positive direction in girls as a result of the intervention with parental support.     

Meetings

ABSTRACT

This exploratory study builds on existing research on the physiological stress response to human–animal interactions in a non-clinical sample of adult dog-owners interacting with their own or an unfamiliar therapy dog under similar conditions. Participants were therapy-dog owners (TDO group; n = 5) interacting with their own dogs and dog owners interacting with an unfamiliar therapy dog (AAA group; n = 5). Following a 30minute baseline period, participants completed a stress task followed by a 30-minute dog interaction and then watched a neutral video for 60 minutes. The outcome variable of interest was the bio-behavioral stress response, measured by systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), salivary cortisol, salivary alpha-amylase, and self-report. Trait anxiety and attitudes toward pets were assessed as moderating variables. Results revealed consistent physiological patterns, showing modest increases with the stressor and decreases from baseline following the intervention, for salivary cortisol, SBP, DBP, HR, and self reported anxiety and stress for both groups. In general, although the TDO group tended to perceive less stress and anxiety during the intervention than the AAA group, greater reductions in physiological measures were observed in the AAA group. Positive attitudes toward pets in the total sample of dog owners were associated with decreased levels of self-reported stress (p < 0.05), salivary cortisol, and SBP, while higher levels of trait anxiety were associated with higher levels of salivary cortisol (p < 0.05). In addition, higher levels of trait anxiety were associated with lower levels of autonomic nervous system indicators of stress (HR; SBP, p < 0.05; DBP, p < 0.05). Results support a buffering effect on the stress response associated with owners interacting with their dogs that may extend to interactions with unfamiliar therapy dogs in AAA, and supports the need for replication studies with larger sample sizes.     

Pet's Presence and Owner's Blood Pressures during the Daily Lives of Pet Owners with Pre- to Mild Hypertension

ABSTRACT

As the population ages the number of older adults living with hypertension (HTN) is rising dramatically. Uncontrolled HTN increases cardiovascular and renal mortality. Ambulatory (A) blood pressure (BP) is a better predictor of HTN-related morbidity and mortality than office BP. Lower BP is the most important therapeutic goal in treating HTN. Any reduction in BP has significant benefits for older adults. The current study was designed to evaluate the impact of the presence of pet dogs and cats on ABP during the daily lives of independently living, older pet owners with pre- to mild HTN. A repeated measures observational study of ABP of 32 pet owners (21 dogs, 8 cats, 3 cat and dog; 29 women) aged 50–83 years with BP 120–150/80–100 mmHg or < 150/100 with anti-hypertensive medication was conducted. Owner's ABPs were recorded every 20 minutes for one day during waking hours at study entry, one month, and three months. Activity monitors and diaries were used to obtain information about activity, mood, and whether the pet and/or another person was present in the room (indoors) or in close proximity (outdoors) with the owner at each assessment. Generalized estimating equation (GEE) analyses for hierarchical data (unstructured correlations) were performed for systolic and diastolic ABP. Mean ABPs were significantly (systolic BP/diastolic BP: dog p = 0.008/ p = 0.002; cat p < 0.009/ p < 0.001) different (systolic BP/diastolic BP mmHg: dog 3.1/1.5; cat –3.0/2.2) when pets were present after controlling for participant's mood (p > 0.05/ p < 0.001), activity intensity (p = 0.026/ p = 0.441), location (p = 0.013/ p = 0.004), and the presence of other people (p = 0.947/ p = 0.723). The presence of a dog was associated with lower systolic and diastolic BP and of a cat was associated with lower diastolic BP and higher systolic BP during their owners' normal daily lives. This finding suggests that pets, especially dogs, may be effective as an adjunctive intervention to slow the development or progression of HTN in older adults. Comparison of ABPs of pet owners with non-owners during their daily lives is warranted and underway.     

奥氮平联合重复经颅磁刺激或改良电休克治疗精神分裂症的疗效分析

目的:比较抗精神病药物奥氮平联合复经颅磁刺激(rTMS)或改良电休克(MECT)治疗精神分裂症的疗效。方法:将84例精神分裂症患者随机分为rTMS组(42例)与MECT组(42例),两组分别在奥氮平的基础上联合MECT或rTMS进行治疗。在治疗2、4、8周末后,采用阳性症状和阴性症状量表PANSS、治疗时出现症状量表TESS评估临床治疗效果及不良反应,同时采用修订韦氏记忆量表(WMS-RC)和威斯康星卡片分类测验(WCST)评定认知功能。结果:治疗后,两组总有效率比较无统计学差异(P0.05)。两组治疗后PANSS总分、阳性症状、阴性症状和一般病理分值均显著低于治疗前(P0.05,P0.01),但组间比较无统计学差异(P0.05)。两组TESS评分及不良反应的发生情况比较无统计学差异(P0.05)。与治疗前相比,两组患者治疗后认知功能均显著改善(P0.05,P0.01),且rTMS联合组在改善患者记忆功能、执行能力方面效果优于MTCT组(P0.05)。结论:奥氮平联合MECT或rTMS对精神分裂症状的疗效相当,但联合rTMS可更显著改善患者的认知功能。     

利培酮联合小剂量阿立哌唑对精神分裂症患者血清神经递质、糖脂代谢及BMI的影响

目的:探讨利培酮联合小剂量阿立哌唑治疗对精神分裂症患者血清神经递质、糖脂代谢及体质量指数(BMI)的影响。方法:选取2016年1月～2018年10月期间我院收治的80例精神分裂症患者,根据随机数字表法将患者分为对照组(n=40)和研究组(n=40),对照组予以利培酮治疗,研究组在对照组基础上联合小剂量阿立哌唑治疗,比较两组患者疗效、阳性和阴性症状评定量表(PANSS)评分、血清神经递质[多巴胺、去甲肾上腺素(NE)、5-羟吲哚乙酸(5-HIAA)]和糖脂代谢[血糖(FPG)、总胆固醇(TC)、三酰甘油(TG)],记录两组治疗期间不良反应情况。结果:研究组治疗4周后临床总有效率为97.50%(39/40),高于对照组的82.50%(33/40)(P0.05)。两组治疗4周后PANSS中的阴性症状评分、阳性症状评分、一般病理评分、总分、FPG、TC、TG及血清多巴胺水平均较治疗前下降,且研究组低于对照组(P0.05)。两组患者治疗4周后血清NE、5-HIAA水平均升高,且研究组高于对照组(P0.05)。两组患者治疗4周后BMI均略有增加,但差异无统计学意义(均P0.05)。研究组、对照组不良反应总发生率分别为15.00%(6/40)、12.50%(5/40),二者比较无差异(P0.05)。结论:利培酮联合小剂量阿立哌唑治疗精神分裂症患者可提高其临床疗效,可有效改善血清神经递质水平,对机体糖脂代谢和BMI影响轻微,且用药安全性较好。     

Association polymorphic variants of GRIN2B gene with paranoid schizophrenia and response to typical neuroleptics in Russians and Tatars from Bashkortostan Republic

An analysis of the association of paranoid schizophrenia seeking with polymorphic variants of GRIN2B was performed in order to identify genetic risk factors of disease development and genetic markers of the response to therapy by neuroleptics in Russian and Tatar patients from Bashkortostan Republic (BR). In the course of the analysis, we revealed the following: (1) genetic markers of increased risk of developing paranoid schizophrenia in various ethnic groups, including, in Tatars, the GRIN2B*T/*T genotype (p = 0.003; OR = 2.33) and GRIN2B*T allele (p = 0.001; OR = 2.36), rs1805247; in Russians, the GRIN2B*T/*T genotype (p = 0.038; OR = 2.12) and GRIN2B*T allele (p = 0.028; OR = 2.03), rs1805247, genotype GRIN2B*A/*A (p = 0.042; OR = 2.12), rs1805476; (2) genetic markers of the reduced risk of developing paranoid schizophrenia; (3) genetic markers of therapy response and the risk of side effects development during neuroleptics (haloperidol) treatment in Bashkortostan. The significant interethnic diversity of genetic factors related to the risk of this disease development was noted.